Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03488810 | Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer(ARN-509) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 17, 2020 | clinicaltrials |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma(PIVOT-RCC) | withdrawn | Phase 2 | 0 | Washington University School of Medicine |
| 0 |
| Aug 13, 2020 |
| clinicaltrials |
| NCT03115593 | Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer | withdrawn | N/A | 0 | Brugmann University HospitalOTHER | 2 | Aug 7, 2020 | clinicaltrials |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | withdrawn | Phase 1 | 0 | NanOlogy, LLCINDUSTRY | 0 | Aug 4, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03596710 | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT04272645 | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04411134 | E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04073160 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer(TRIO Bladder) | withdrawn | Phase 1 | 0 | Daniel George, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03583736 | Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jun 30, 2020 | clinicaltrials |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | withdrawn | Phase 2 | 0 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 12, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02430649 | Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms(IRE) | withdrawn | N/A | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT03748719 | Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | May 22, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Loma Linda UniversityOTHER | 1 | Apr 30, 2020 | clinicaltrials |
| NCT01019278 | Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01766869 | Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS(GCC 1261) | withdrawn | — | 0 | University of Maryland, BaltimoreOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT03817216 | Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Mar 12, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02811809 | Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2020 | clinicaltrials |
| NCT03146039 | Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB(NICER) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | withdrawn | — | 0 | University of SouthamptonOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor.(R3DP-A) | withdrawn | N/A | 0 | University Hospital, BordeauxOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02647983 | Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection | withdrawn | Phase 1 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | withdrawn | Phase 3 | 0 | BayerINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01633255 | [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT01766622 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | withdrawn | Phase 2 | 0 | National Institutes of Health Clinical Center (CC)NIH | 0 | Dec 4, 2019 | clinicaltrials |
| NCT03293602 | MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imaging(MISOBOLD) | withdrawn | N/A | 0 | University Hospital, BordeauxOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00880854 | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT00980993 | Quantification of Respiratory-induced Prostate Motion | withdrawn | — | 0 | Oregon Health and Science UniversityOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03795272 | Rucaparib Maintenance Therapy in Advanced Cervical Cancer(MaRuC) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer(TopoTxt) | withdrawn | — | 0 | Carilion ClinicOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT03514927 | High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | withdrawn | — | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03157947 | Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 5, 2019 | clinicaltrials |
| NCT03528057 | Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | withdrawn | N/A | 0 | Northwestern UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2020source: clinicaltrials